Published in Mol Cancer Ther on February 01, 2003
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer (2004) 1.40
Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma. Onco Targets Ther (2016) 0.79
Alpha cyano-4-hydroxy-3-methoxycinnamic acid inhibits proliferation and induces apoptosis in human breast cancer cells. PLoS One (2013) 0.76
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A (2002) 9.60
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol (2003) 2.29
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
Paget disease of bone. J Clin Invest (2005) 1.92
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Targeting Axl and Mer kinases in cancer. Mol Cancer Ther (2011) 1.88
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res (2007) 1.66
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology (2015) 1.56
Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest (2006) 1.52
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer (2005) 1.43
A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet (2008) 1.33
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology (2012) 1.32
Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res (2007) 1.29
The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One (2009) 1.29
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res (2005) 1.22
Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell (2008) 1.20
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol (2002) 1.17
Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood (2009) 1.16
Telomeres and telomerases as drug targets. Curr Opin Pharmacol (2002) 1.14
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res (2007) 1.11
MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics (2014) 1.10
Osteoclasts are important for bone angiogenesis. Blood (2009) 1.08
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res (2006) 1.06
Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res (2002) 1.04
Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One (2012) 1.02
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia (2007) 1.01
High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J Med Chem (2013) 0.98
MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem (2011) 0.98
Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res (2009) 0.97
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res (2012) 0.97
Retracted Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2004) 0.97
Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology (2002) 0.96
Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene (2002) 0.96
In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation. DNA Repair (Amst) (2009) 0.95
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One (2013) 0.93
Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett (2011) 0.93
Laminin-5 beta3A expression in LNCaP human prostate carcinoma cells increases cell migration and tumorigenicity. Neoplasia (2004) 0.92
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. Cancer Res (2006) 0.91
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther (2006) 0.91
Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med (2012) 0.90
ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo. J Bone Miner Res (2011) 0.89
Activators of PKM2 in cancer metabolism. Future Med Chem (2014) 0.89
Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer. Gene (2004) 0.88
Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor. PLoS One (2013) 0.88
Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol (2011) 0.87
Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci (2005) 0.86
Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol (2011) 0.85
Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther (2007) 0.84
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther (2006) 0.84
Experimental models of Paget's disease. J Bone Miner Res (2006) 0.84
Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis. J Biol Chem (2012) 0.84
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther (2003) 0.84
TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res (2014) 0.83
Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. J Bone Miner Res (2014) 0.83
A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer. Prostate (2005) 0.83
TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res (2013) 0.82
Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents (2003) 0.82
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. Prostate (2008) 0.82
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology (2007) 0.82
Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol (2002) 0.82
Ultrastructure of bone cells in Paget's disease of bone. J Bone Miner Res (2006) 0.82
Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem (2010) 0.81
Split tolerance in a novel transgenic model of autoimmune myasthenia gravis. J Immunol (2002) 0.81
Using boronolectin in MALDI-MS imaging for the histological analysis of cancer tissue expressing the sialyl Lewis X antigen. Chem Commun (Camb) (2011) 0.81
Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology. Cancer Res (2003) 0.80
Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol (2007) 0.80
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice. Pancreas (2008) 0.80
Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease. J Bone Miner Res (2013) 0.79
In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol (2010) 0.79
The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. J Urol (2005) 0.79
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Expert Rev Anticancer Ther (2011) 0.79
Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Exp Cell Res (2010) 0.78
A preliminary study of the baboon prostate pathophysiology. Prostate (2007) 0.78
Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. J Clin Invest (2016) 0.78
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. J Urol (2009) 0.77
Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling. Bone (2012) 0.77
Phenotypic characterization of transgenic mice harboring Nf1+/- or Nf1-/- osteoclasts in otherwise Nf1+/+ background. J Cell Biochem (2012) 0.76
Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure. FASEB J (2014) 0.75
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol (2016) 0.75
Patterns and Significance of PIM Kinases in Urothelial Carcinoma. Appl Immunohistochem Mol Morphol (2015) 0.75
Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2005) 0.75
Potential mouse tumor model for pre-clinical testing of mage-specific breast cancer vaccines. Breast Cancer Res Treat (2002) 0.75